Analysis
Benchmark survey: make your voice heard
In Analysis
Bookmark
Record learning outcomes
Independent Community Pharmacist and CIG Research are updating their 2017 research looking at the key issues affecting the sector – and want to hear your views.
It has been an incredibly challenging period, one which saw the funding cuts really begin to bite, the demise of Pharmacy Voice, chronic medicine shortages and dramatic generic price hikes.
PSNC and the NPA took the Department of Health to the High Court over the way the cuts were implemented, supervision dominated the agenda, there were the LloydsPharmacy closures and Parliament finally approved legislation to protect pharmacists from prosecution for making inadvertent dispensing errors.
The year ahead promises to be equally testing. Workplace pressures are in the news, there will be the introduction of revalidation for pharmacists and pharmacy technicians, and Which? investigators will once again turn their attention to pharmacy OTC sales.
All of these issues – and many more besides – have a direct effect on you and your day-to-day practice. To help us build an accurate picture of the impact these events are having, please click on this link to participate in our latest pharmacist attitudinal survey.
You may choose to remain anonymous, but if you include your contact details, they will be completely confidential to CIG Research and will not be used for any other purpose than to monitor your reward points for taking part in our regular survey activity.
This survey will take about 10 minutes to complete and you will earn 100 reward points for completing it. Together with points you may have already accrued if you have taken part in these surveys before, you can redeem these for Amazon vouchers worth £20 for every 500 points you accumulate.
Your responses will help shape our reporting in the coming months and send out a powerful message about the state of pharmacy in 2018 – so don’t miss the opportunity to have your say and make your voice heard.
Click here to take part.